13
Mar
2025

Protagonist Delivers, BMS Bargain Hunts, and Zealand Goes Major League

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

FDA in Crisis, Parker Institute Snags Big Fish, & Merida Megaround
FDA Gutted, Novartis Kidney Drug Pays Off, and Isomorphic Raises a Fortune
A Moment of Peril and Promise
Curevo and Arbor Defy Gravity, Cargo Hits the Wall, & AZ Bets on In Vivo